Will Valeant price its new psoriasis med at a discount to rivals to reflect its hefty suicide risk-management program? And if not, can it still compete?…

A Genentech lobbyist who generated enormous sales for the company allegedly kept millions in consulting payments to himself.

​​​​​​​Pharma has heard enough of New York Governor Andrew Cuomo’s ideas to lower drug prices, and it's lobbying state officials to oppose it, too.

Greek prosecutors have raided Novartis offices and questioned 178 people in a bribery investigation launched after corruption allegations surfaced in local…

Years after wrapping up Abilfy marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar…

Beating the street to market painkillers in Chicago? You might need a special license for that soon.

Bristol-Myers Squibb has gotten more bad news in its efforts to grow lung cancer sales. England's cost watchdog has turned it down, although the regulator…

Vertex won a label expansion for cystic fibrosis combo Orkambi late Wednesday--but, as expected, the company lowered its full-year guidance for the med, too.…

Congress is starting to get some answers on EpiPen pricing. And though, so far, Mylan’s not offering much beyond what’s readily available via Google search,…

Regulatory